Your browser doesn't support javascript.
loading
Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report.
Li, Dan; Zhu, Yue; Song, Jincheng; Yang, Dafu; Cui, Saiqiong; Liu, Xin; Wang, Le; Zhang, Jiangyan; Pan, Evenki; Dai, Zhaoxia.
Afiliación
  • Li D; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Zhu Y; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Song J; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Yang D; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Cui S; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Liu X; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Wang L; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Zhang J; Department of Medical Services, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
  • Pan E; Department of Medical Services, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
  • Dai Z; Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Front Oncol ; 14: 1339511, 2024.
Article en En | MEDLINE | ID: mdl-38699646
ABSTRACT
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance. Resistance mechanisms to ALK TKIs can be broadly classified into ALK-dependent and ALK-independent pathways. Here, we present a case with lung adenocarcinoma (LUAD) harboring an ALK rearrangement. The patient had developed resistance to sequential ALK TKI therapies, with an acquired ETV6-NTRK3 (E4N14) fusion as a potential mechanism of ALK-independent resistance to lorlatinib. Subsequently, the patient was treated with the combination of brigatinib plus entrectinib and demonstrated a positive response, achieving an 8-month progression-free survival. Our case provides a potential treatment option for LUAD patients with ALK rearrangements and highlights the utility of next-generation sequencing (NGS) in uncovering genetic alterations that can guide the selection of effective treatment strategies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article